🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with blood pressure went from scary to perfect - anyone else?? Page 4

Has anyone dealt with blood pressure went from scary to perfect - anyone else??

sophie_paris Thu, Oct 31, 2024 at 3:24 AM 39 replies 2,318 viewsPage 4 of 8
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Nov 12, 2024 at 3:28 PM#16

From the other side of the consultation, briefly.

TomFromTexas said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

Last edited: Nov 12, 2024 at 4:28 PM
11 9zoe_NC, Dr.ObesityLA, NurseKim_ATL and 8 others
Reply Quote Save Share Report
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Nov 14, 2024 at 7:20 AM#17

Following on from TomFromTexas — and this may be the naive question:

Was that from a primary source or from a summary of one?

Last edited: Nov 14, 2024 at 8:20 AM
12 10AttorneyGrant, DebRD_ATL, KristenIndy and 9 others
Reply Quote Save Share Report
adam_van
Member
212
890
Nov 2024
Vancouver, CA
Nov 15, 2024 at 11:13 PM#18
Dr.ObesityLA said:
TomFromTexas said: ...cardiovascular risk is just another fad...

Senior perspective on cardiovascular risk: I'm 62 years old and started this journey skeptically. My cardiologist recommended it after years of failed interventions.

14 months later: down 50 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.

To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.

13 11LindaRN_retired, tommy_boulder, hyun_seoul and 10 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Nov 17, 2024 at 3:07 PM#19
Dr.ObesityLA said:
TomFromTexas said: ...cardiovascular risk is just another fad...

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
14 12LabKate, kate.chem, DataDave and 11 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Nov 19, 2024 at 7:02 AM#20

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Carry on.

36 9PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 33 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register